Benign prostatic hyperplasia (BPH) also known as benign prostatic hypertrophy is characterized by the unusual propagation of the prostatic cells, which causes difficulties like urinary retention and infections of the urinary tract. It is most common among the aging men population, primarily driving this market. On the basis of geographical analysis, the North American region is expected to retain its dominance in this market owing to better healthcare infrastructure, high healthcare expenditure on urological disorders, increased awareness in the society increasing the outpatients center and hospitals visits.
The global Benign Prostatic Hyperplasia market size is projected to grow from US$ 10000 million in 2023 to US$ 14050 million in 2030; it is expected to grow at a CAGR of 5.0% from 2024 to 2030.
The 鈥淏enign Prostatic Hyperplasia Industry Forecast鈥� looks at past sales and reviews total world Benign Prostatic Hyperplasia sales in 2023, providing a comprehensive analysis by region and market sector of projected Benign Prostatic Hyperplasia sales for 2024 through 2030. With Benign Prostatic Hyperplasia sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Benign Prostatic Hyperplasia industry.
This Insight Report provides a comprehensive analysis of the global Benign Prostatic Hyperplasia landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Benign Prostatic Hyperplasia portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Benign Prostatic Hyperplasia market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Benign Prostatic Hyperplasia and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Benign Prostatic Hyperplasia.
United States market for Benign Prostatic Hyperplasia is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Benign Prostatic Hyperplasia is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Benign Prostatic Hyperplasia is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Benign Prostatic Hyperplasia players cover Abbott, Allergan, Astellas Pharma, Boehringer Ingelheim Pharma and Eli Lilly and Company, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Benign Prostatic Hyperplasia market by product type, application, key players and key regions and countries.
Segmentation by type
Drug Therapy
Dialysis
Others
Segmentation by application
Hospitals
Clinics
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott
Allergan
Astellas Pharma
Boehringer Ingelheim Pharma
Eli Lilly and Company
GlaxoSmithKline
Merck
Pfizer
Sanofi
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Benign Prostatic Hyperplasia Market Size 2019-2030
2.1.2 Benign Prostatic Hyperplasia Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Benign Prostatic Hyperplasia Segment by Type
2.2.1 Drug Therapy
2.2.2 Dialysis
2.2.3 Others
2.3 Benign Prostatic Hyperplasia Market Size by Type
2.3.1 Benign Prostatic Hyperplasia Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Benign Prostatic Hyperplasia Market Size Market Share by Type (2019-2024)
2.4 Benign Prostatic Hyperplasia Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.5 Benign Prostatic Hyperplasia Market Size by Application
2.5.1 Benign Prostatic Hyperplasia Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Benign Prostatic Hyperplasia Market Size Market Share by Application (2019-2024)
3 Benign Prostatic Hyperplasia Market Size by Player
3.1 Benign Prostatic Hyperplasia Market Size Market Share by Players
3.1.1 Global Benign Prostatic Hyperplasia Revenue by Players (2019-2024)
3.1.2 Global Benign Prostatic Hyperplasia Revenue Market Share by Players (2019-2024)
3.2 Global Benign Prostatic Hyperplasia Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Benign Prostatic Hyperplasia by Regions
4.1 Benign Prostatic Hyperplasia Market Size by Regions (2019-2024)
4.2 Americas Benign Prostatic Hyperplasia Market Size Growth (2019-2024)
4.3 APAC Benign Prostatic Hyperplasia Market Size Growth (2019-2024)
4.4 Europe Benign Prostatic Hyperplasia Market Size Growth (2019-2024)
4.5 Middle East & Africa Benign Prostatic Hyperplasia Market Size Growth (2019-2024)
5 Americas
5.1 Americas Benign Prostatic Hyperplasia Market Size by Country (2019-2024)
5.2 Americas Benign Prostatic Hyperplasia Market Size by Type (2019-2024)
5.3 Americas Benign Prostatic Hyperplasia Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Benign Prostatic Hyperplasia Market Size by Region (2019-2024)
6.2 APAC Benign Prostatic Hyperplasia Market Size by Type (2019-2024)
6.3 APAC Benign Prostatic Hyperplasia Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Benign Prostatic Hyperplasia by Country (2019-2024)
7.2 Europe Benign Prostatic Hyperplasia Market Size by Type (2019-2024)
7.3 Europe Benign Prostatic Hyperplasia Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Benign Prostatic Hyperplasia by Region (2019-2024)
8.2 Middle East & Africa Benign Prostatic Hyperplasia Market Size by Type (2019-2024)
8.3 Middle East & Africa Benign Prostatic Hyperplasia Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Benign Prostatic Hyperplasia Market Forecast
10.1 Global Benign Prostatic Hyperplasia Forecast by Regions (2025-2030)
10.1.1 Global Benign Prostatic Hyperplasia Forecast by Regions (2025-2030)
10.1.2 Americas Benign Prostatic Hyperplasia Forecast
10.1.3 APAC Benign Prostatic Hyperplasia Forecast
10.1.4 Europe Benign Prostatic Hyperplasia Forecast
10.1.5 Middle East & Africa Benign Prostatic Hyperplasia Forecast
10.2 Americas Benign Prostatic Hyperplasia Forecast by Country (2025-2030)
10.2.1 United States Benign Prostatic Hyperplasia Market Forecast
10.2.2 Canada Benign Prostatic Hyperplasia Market Forecast
10.2.3 Mexico Benign Prostatic Hyperplasia Market Forecast
10.2.4 Brazil Benign Prostatic Hyperplasia Market Forecast
10.3 APAC Benign Prostatic Hyperplasia Forecast by Region (2025-2030)
10.3.1 China Benign Prostatic Hyperplasia Market Forecast
10.3.2 Japan Benign Prostatic Hyperplasia Market Forecast
10.3.3 Korea Benign Prostatic Hyperplasia Market Forecast
10.3.4 Southeast Asia Benign Prostatic Hyperplasia Market Forecast
10.3.5 India Benign Prostatic Hyperplasia Market Forecast
10.3.6 Australia Benign Prostatic Hyperplasia Market Forecast
10.4 Europe Benign Prostatic Hyperplasia Forecast by Country (2025-2030)
10.4.1 Germany Benign Prostatic Hyperplasia Market Forecast
10.4.2 France Benign Prostatic Hyperplasia Market Forecast
10.4.3 UK Benign Prostatic Hyperplasia Market Forecast
10.4.4 Italy Benign Prostatic Hyperplasia Market Forecast
10.4.5 Russia Benign Prostatic Hyperplasia Market Forecast
10.5 Middle East & Africa Benign Prostatic Hyperplasia Forecast by Region (2025-2030)
10.5.1 Egypt Benign Prostatic Hyperplasia Market Forecast
10.5.2 South Africa Benign Prostatic Hyperplasia Market Forecast
10.5.3 Israel Benign Prostatic Hyperplasia Market Forecast
10.5.4 Turkey Benign Prostatic Hyperplasia Market Forecast
10.5.5 GCC Countries Benign Prostatic Hyperplasia Market Forecast
10.6 Global Benign Prostatic Hyperplasia Forecast by Type (2025-2030)
10.7 Global Benign Prostatic Hyperplasia Forecast by Application (2025-2030)
11 Key Players Analysis
11.1 Abbott
11.1.1 Abbott Company Information
11.1.2 Abbott Benign Prostatic Hyperplasia Product Offered
11.1.3 Abbott Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Abbott Main Business Overview
11.1.5 Abbott Latest Developments
11.2 Allergan
11.2.1 Allergan Company Information
11.2.2 Allergan Benign Prostatic Hyperplasia Product Offered
11.2.3 Allergan Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Allergan Main Business Overview
11.2.5 Allergan Latest Developments
11.3 Astellas Pharma
11.3.1 Astellas Pharma Company Information
11.3.2 Astellas Pharma Benign Prostatic Hyperplasia Product Offered
11.3.3 Astellas Pharma Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Astellas Pharma Main Business Overview
11.3.5 Astellas Pharma Latest Developments
11.4 Boehringer Ingelheim Pharma
11.4.1 Boehringer Ingelheim Pharma Company Information
11.4.2 Boehringer Ingelheim Pharma Benign Prostatic Hyperplasia Product Offered
11.4.3 Boehringer Ingelheim Pharma Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Boehringer Ingelheim Pharma Main Business Overview
11.4.5 Boehringer Ingelheim Pharma Latest Developments
11.5 Eli Lilly and Company
11.5.1 Eli Lilly and Company Company Information
11.5.2 Eli Lilly and Company Benign Prostatic Hyperplasia Product Offered
11.5.3 Eli Lilly and Company Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Eli Lilly and Company Main Business Overview
11.5.5 Eli Lilly and Company Latest Developments
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Information
11.6.2 GlaxoSmithKline Benign Prostatic Hyperplasia Product Offered
11.6.3 GlaxoSmithKline Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 GlaxoSmithKline Main Business Overview
11.6.5 GlaxoSmithKline Latest Developments
11.7 Merck
11.7.1 Merck Company Information
11.7.2 Merck Benign Prostatic Hyperplasia Product Offered
11.7.3 Merck Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Merck Main Business Overview
11.7.5 Merck Latest Developments
11.8 Pfizer
11.8.1 Pfizer Company Information
11.8.2 Pfizer Benign Prostatic Hyperplasia Product Offered
11.8.3 Pfizer Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Pfizer Main Business Overview
11.8.5 Pfizer Latest Developments
11.9 Sanofi
11.9.1 Sanofi Company Information
11.9.2 Sanofi Benign Prostatic Hyperplasia Product Offered
11.9.3 Sanofi Benign Prostatic Hyperplasia Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Sanofi Main Business Overview
11.9.5 Sanofi Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
